Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with <i>Clostridioides difficile</i> Infection: A Phase 2a Multicenter Clinical Trial

Abstract

In this phase 2a study, 10 of 10 patients achieved SCC, demonstrated favorable pharmacokinetics, minimal AEs, and beneficial microbiome and bile acids results. These results support continued clinical development.